藥 名
永康
柳營
佳里
|
更新日期：09/28/2018 13:47:07
CefTRIaxone(1g/V)針
|
現行藥品外觀
11C170
健保
|
中文名：信得瑞注射劑
健保碼：AB36751209
廠 牌：信東
|
|
藥理分類
J01DD04
|
【Antibacterials for systemic use】
Third-generation cephalosporins
|
|
|
藥理作用
|
|
|
Product name
|
Sintrix (1gm/V)針.
|
|
Dosage form
|
Inj. 1g/Vial
|
|
Administration & Dosage
|
【Adult】
●Dosage range: IM, IV: Usual dose: 1-2 g q12-24h
●Cholecystitis and Intra-abdominal infection, mild-to-moderate: IV: 1-2 g q12-24h for 4-7 day.
●Meningitis, community-acquired (empiric): IV: 2 g q12h for 7-14 days
●Pelvic inflammatory disease (mild to moderately severe): IM: 250 mg in a single dose plus oral doxycycline (+/- oral metronidazole)
●Pneumonia, community-acquired: IM, IV: 1 to 2 g/day in 1-2 divided doses.
●Prosthetic joint infection: IV, Streptococci, beta-hemolytic: 2 g qd for 4-6 weeks
●Urinary tract infection, complicated: IV, IM: 1-2 g/day.
【Pediatric】
●Dosage range:
*Mild-to-moderate infections: 50-75mg/kg/d divided to q12-24h (Max: 2g/d).
*Serious infections: 80-100mg/kg/d divided 1-2 doses (Max: 4g/d)
●Gonococcal infections:
*Children ≦45 kg: 50 mg/kg/dose once daily (maximum: 1,000 mg) for 7 days
*Children >45 kg: 1,000 mg once daily for 7 days
●Meningitis: 100mg/kg/d IV/IM divided q12-24h; Max. 4g/d.
●Skin/skin structure infections: IM, IV: 50 to 75 mg/kg/day divided to q12-24h(max: 2g/d)
|
|
建議給藥途徑
|
IM、IV推、IV滴
|
|
腎功能劑量建議
|
無特別標註
|
|
肝功能劑量建議
|
無特別標註
|
|
Contraindication
|
concurrent administration of calcium-containing solutions or products in newborns(risk of fatal salt precipitation in lungs and kidneys); hypersensitivity to cephalosporins;neonates, hyperbilirubinemic(especially in premature neonates).
|
|
Precaution
|
|
|
Adverse reaction
|
【>10%】 Skin tightness, induration at injection site.
【1% -10%】Skin rash, diarrhea, eosinophilia, thrombocythemia, leukopenia, increased serum transaminases, pain at injection site, tenderness at injection site, increased blood urea nitrogen
【<1%】not referred here, please see package insert ot other reference.
|
|
Pregnancy Category
|
B / 可能安全
|
|
Notes
|
1. Should be used with caution when administered to hyperbilirubinemic neonates, especially premature.
2. Na content: 83mg/vial, 3.6meq/vial
3. Ceftriaxone binds to calcium forming an insoluble precipitate. Management: Use of ceftriaxone is contraindicated in neonates (28 days of age or younger) who require (or are expected to require) treatment with IV calcium-containing solutions.
|
|
相關連結
|
|
|
磨粉及剝半提示 |
無特別標註
|
|
給藥及保存方式 |
1)可用10ml無菌注射用水配製後,
IV推 >2-4分鐘.
2)或加入不含鈣之輸液中,
IV滴 >30分鐘.
IVD 稀釋成濃度為<=40 mg/ml
IVP 稀釋成濃度為<=100 mg/ml
配置後溶液25℃可保存12hr,
2-8℃可保存24hr.
|
針劑相容溶液
*為文獻資料 |
G5W, G10W, N.S.
| 途徑 | 溶解液 | 溶解液量(ml) | 溶解後總量(ml) | | IM | Water for inj. (20ml/A) 針. | 3.50 | 3.50 | | IV推 | Water for inj. (20ml/A) 針. | 10.00 | 10.00 | | IV滴 | Water for inj. (20ml/A) 針. | 10.00 | 10.00 |
|
| 健保給付規定 |
藥品說明：
1)fluoroquinolone類若使用於結核病不予給付2)門診使用抗微生物製劑以不超過3日為原則,7日為限;慢性骨髓炎病患得視病情需要延長給藥日數,每次14日為上限 3)若微生物培養證明第一線抗微生物製劑有效,應考慮改用第一線抗微生物製劑 4)使用抗微生物製劑,宜以同療效,價廉為原則.
藥品理由：
01 合乎健保之給付病情,需直接使用第一線以外抗生素正進行菌種培養,請說明病情理由.
02 一線抗生素藥物敏感報告有效,仍需使用2,3線抗生素者,請說明理由.
03 已使用一線抗生素超過72 hrs, 且藥物敏感性試驗對第一線抗生素具抗藥性.
04 已於本院或其他醫院使用不同之一線抗生素7日以上仍無效者.
05 嬰幼兒(2m - 5yrs),患疑似感染疾病,在使用一線抗生素72小時仍無效者.
06 Ceftriaxone用於疑似或證實為淋病尿道炎、子宮頸炎、軟性下疳時，可第一線單一劑量使用。
07 Cefixime用於疑似或證實為淋病尿道炎、子宮頸炎、軟性下疳時，可第一線單一劑量使用。
08 感染高風險之免疫不全病人預防使用
|
舊藥品外觀
|
中文名：西華耑隆乾粉注射劑1克
廠 牌：LABESFAL
|